GSK and Theravance, Inc. have announced that the Breo Ellipta fluticasone furoate/vilanterol DPI has been approved in Canada in 100/25 mcg and 200/25 mcg versions for the treatment of asthma in patients aged 18 years and older. Breo Ellipta was approved in Canada for the treatment of COPD in July 2013.
Theravance, Inc. President and CEO Michael W. Aguiar commented, “With today’s approval of Breo Ellipta in Canada, we are pleased to expand the number of patients able to benefit from this important medicine. As a once-daily ICS/LABA treatment for adults with asthma, people suffering from this chronic condition now have an additional option.”
Read the GSK/Theravance press release.
